Business Wire

C3 Releases Low-Code/No-Code AI Development Environment for Enterprise AI

Del

C3, the leading enterprise AI software provider for accelerating digital transformation, today introduced the C3 Integrated Development Studio (IDS), a low-code/no-code environment for developing, deploying, and operating enterprise AI applications. IDS provides data ingestion, data modeling, machine learning feature engineering and model lifecycle management, and a metadata-driven UI development tool. The hybrid, multi-cloud distributed architecture of C3 IDS enables secure, highly available, and rapidly scalable application development.

C3 IDS delivers an improved developer experience through a low-code/no-code environment that accelerates developer velocity, an important capability for building complex enterprise-scale applications on the C3 AI Suite. C3 customers have already built end-to-end applications for a wide range of use cases on C3 IDS, including predictive maintenance and yield optimization. Based on recent analysis by an independent system integrator, building an application on the C3 AI Suite is at least 25x faster—and is typically 50x to 100x faster—than using existing cloud microservices.

“With C3 IDS, we rapidly developed and deployed a predictive maintenance AI application into production,” said Ryan Gross, a leader in the Machine Learning practice at strategic services and information technology consulting company Pariveda Solutions. “The low-code/no-code environment provided well-integrated solutions for many of the problems we have spent great time and effort to solve in the past, from data integration and data modeling to machine learning and application development. Developing and deploying this application in a week would have been impossible without C3 IDS.”

First-of-Its-Kind AI Application Development Platform

C3 IDS allows developers and data scientists to focus on solving business problems by providing a single integrated environment that abstracts routine and complex application development tasks, through four environments:

  • C3 Data Studio: Ingest data of any kind and size through a browser-based interface; process, query, and plug the data into applications; connect to existing databases; define transformations; and develop or extend application objects (e.g., data model, analytics, algorithms, UI). Developers can also extend prebuilt industry and functional application packages to accelerate development.
  • C3 App Studio: Develop analytics through a visual interface and a metadata-driven UI Designer to develop an application front end.
  • C3 ML Studio: Manage prebuilt machine learning pipelines, machine learning model development, and hyper-parameter tuning. Integrate all popular machine learning libraries including TensorFlow, Keras, Scikit-Learn, and more, in composable AI/machine learning pipelines.
  • C3 DevOps Studio: Access all essential DevOps functions including source control, continuous integration/continuous deployment as a fully managed service, resource monitoring, queue management, task scheduling, and more.

C3 IDS abstracts the complexities of hundreds of cloud platform services (e.g., AWS RDS, Amazon S3, AWS Kinesis, Azure Event Hubs, Amazon DynamoDB, Azure IoT Hub, Google BigQuery, Google Cloud ML Engine, etc.) and thousands of developer tools (e.g., Jenkins, Apache Maven, Puppet, GitHub, etc.) to allow developers and data scientists to focus on the business problem they are solving.

C3 IDS is fully integrated with the C3 AI Suite, allowing users of this low-code/no-code environment to collaborate seamlessly with users who prefer writing code.

“C3 has invested $500 million over the past nine years in building the C3 AI Suite, simplifying the ability to develop AI-based applications and reducing the underlying complexities,” said Ed Abbo, C3 president and chief technology officer. “Using the C3 AI Suite, a small team of developers and data scientists can build complex AI applications and roll out large-scale systems with efficiency and accuracy in just months. With C3 IDS, we have taken another step to speed the delivery and economic value of enterprise AI.”

Learn more about IDS features here: https://c3.ai/products/c3-ai-suite/c3-integrated-development-studio/

About C3

C3 is a leading AI software provider for accelerating digital transformation. C3 delivers a comprehensive and proven set of capabilities for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications 25x to 100x faster than alternative approaches. The core of the C3 offering is a revolutionary, extensible, model-driven AI architecture that dramatically enhances data scientist and application developer productivity while future-proofing applications against underlying IT evolution. The C3 AI Suite supports configurable, prebuilt, high-value AI applications for predictive maintenance, fraud detection, sensor network health, supply chain optimization, energy management, anti-money laundering, and customer engagement. www.C3.ai

Contact information

C3 Public Relations:
Bridget Fisher
Allison + Partners
503-290-7303
pr@c3.ai

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 12:00:00 CESTPressemelding

Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan

Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 10:13:00 CESTPressemelding

Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 09:38:00 CESTPressemelding

The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici

Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 08:00:00 CESTPressemelding

Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an

CNT Among SAP’s "Best of the Best"17.5.2019 08:00:00 CESTPressemelding

Since 2005, SAP is honoring the best of the best SAP projects yearly in Europe, Middle East and Africa. In 2018, 280 customers from 15 markets submitted their regional Gold Award-winning projects. CNT Management Consulting from Vienna won Bronze twice – together with its customers HOERBIGER and TANNPAPIER – a happy day for CNT’s CEO Andreas Doerner. "We are now on the podium for the second time with two projects – thanks to the trust of our customers." The SAP Quality Awards EMEA were presented at an exceptionally festive ceremony in Heidelberg Castle (Baden-Wuerttemberg), and only twelve SAP customers were able to take home the most wanted trophies that were presented by SAP Presidents Brian Duffy (EMEA North) and Hartmut Thomsen (Middle and Eastern Europe). The jury evaluated the projects according to the ten SAP quality principles and the question of whether the respective project could fulfill the expectations of its clients. HOERBIGER - Category Business Transformation Headquarter

EVER Pharma acquires Amneal Deutschland GmbH and extends its commercial presence in Europe17.5.2019 07:25:00 CESTPressemelding

EVER Pharma Holding Ges.m.b.H (Austria) announced today that it has completed the acquisition of Amneal Deutschland GmbH, a subsidiary of Amneal Pharmaceuticals that operates the company's commercial operations in Germany. Amneal Deutschland already distributes several EVER Pharma products in Germany and is a strongly established player in the German hospital market. The acquired entity will be rebranded to EVER Pharma GmbH. “This acquisition represents another milestone in the expansion of EVER Pharma’s commercial footprint in Europe. With this new operation, EVER Pharma extends its portfolio in Germany and establishes a solid platform for the growth of its portfolio and pipeline” commented Georges Kahwati, General Manager of EVER Pharma. “We are pleased to establish another EVER affiliate in one of the key European markets in line with our strategy of establishing our own business presence in core markets.” added Julia Hillebrand, Managing Director and Owner. About EVER Pharma: EVER